Patients with corneal damage and considerable vision loss had biosynthetic corneas implanted into their eyes with FibroGen's proprietary rhCIII (recombinant human type III collagen), which restored their vision and promoted nerve regeneration. A report on this 2-year Phase I clinical trial has...